AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

 AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

  • The approval is based on 3 P-III studies i.e., Measure Up 1/2/AD Up evaluating the efficacy & safety of Rinvoq (15/30 mg, qd) as monothx. with TCS vs PBO in 2500+ adults & adolescents with AD
  • The studies met its 1EPs & 2EPs @16wks. i.e., improvement in skin clearance & itch reduction, patients achieved EASI 75 (70%/ 60%/65%) & (80%/ 73%/ 77%) vs (16%/13%/26%); vIGA-AD 0/1 (48%/39%/31%) & (62%/ 52%/ 59%) vs (8%/5%/11%), improvement in Worst Pruritus NRS ≥4 (52%/ 42%/ 52%) & (60%/ 60%/ 64%) vs (12%/ 9%/ 15%). The results continued to be maintained for 52wks.
  • The approval marks the 4th indication in the EU with previous approval in RA, PsA & AS and is approved in the US for RA

Click here to­ read full press release/ article | Ref: Abbvie | Image: Pharma Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post